GlassScriptPhysician profile
Timothy Vreeland
NPI 1497982771
$4,491.65
in general payments reported to CMS, 2019-2025
24 companies · $748 in 2025
The $748 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $176 · 2022: $23.34 · 2023: $101 · 2024: $1,496 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Travel and Lodging: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.17 |
| Travel and Lodging | $839.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,025.73 | 2019 | |
| Histosonics, INC. | $944.78 | 2024 | |
| Medical Device Business Services, INC. | $921.68 | 2019 | |
| Ethicon US, LLC | $254.69 | 2024-2025 | Certus 140, Megadyne, Echelon Flex |
| Dilon Technologies, INC. | $246.57 | 2025 | Hemoblast Bellows |
| Integra Lifesciences Corporation | $175.91 | 2020 | |
| Intera Oncology, INC | $175.02 | 2024 | Intera |
| Hologic Sales and Service, LLC | $124.12 | 2024-2025 | Coolseal Generator |
| Regeneron Healthcare Solutions, INC. | $122.78 | 2025 | Libtayo |
| Tempus Ai, INC | $119.37 | 2024 | |
| Ets Wound Care LLC | $70.74 | 2024 | Mirragen Advanced Wound Matrix |
| Myriad Genetic Laboratories, INC. | $44.39 | 2023 | Myrisk |
| Tersera Therapeutics LLC | $32.49 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $28.08 | 2024 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $23.62 | 2025 | Lynparza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.34 | 2022 | |
| Springworks Therapeutics, INC. | $22.93 | 2025 | Ogsiveo |
| Janssen Biotech, INC. | $22.80 | 2025 | Tecvayli, Talvey |
| Eisai INC. | $20.15 | 2023 | |
| Lilly USA, LLC | $20.06 | 2023 | Verzenio, Jaypirca |
| Pfizer INC. | $19.93 | 2025 | |
| Syndax Pharmaceuticals, INC. | $19.89 | 2025 | |
| Spectrum Pharmaceuticals INC. | $16.53 | 2024 | Rolvedon |
| Stryker Corporation | $16.05 | 2023 | Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Vreeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.